Levy B, Schwarz N, Vaknin Z, Segev Y, Rosengarten O, Perets R, Levy T, Safra T, Magen Z, Fotopoulou C. Increasing Incidence of Endometrial Cancer Demands Global Action. Lancet Obstet Gynaecol Womens Health. 2025;1:e158–9. https://doi.org/10.1016/j.lanogw.2025.10.001.

Article  Google Scholar 

Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, Anand MP, Zheng Y, Zhao R, Li S, Manogaran P, et al. Global Burden of Gynaecological Cancers in 2022 and Projections to 2050. J Glob Health. 2024;14:04155. https://doi.org/10.7189/jogh.14.04155.

Article  PubMed  PubMed Central  Google Scholar 

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

American Cancer Society. Cervical cancer survival rates: Cancer 5 year survival rates. Accessed [December 15, 2025]. Available at: https://www.Cancer.Org/Cancer/Types/Cervical-Cancer/Detection-Diagnosis-Staging/Survival.Html

American Cancer Society. Ovarian cancer survival rates. Accessed [December 15, 2025]. Available at: Https://Www.Cancer.Org https://www.Cancer/Types/Ovarian-Cancer/Detection-Diagnosis-Staging/Survival-Rates.Html

American Cancer Society. Uterine cancer survival rate: survival rates for endometrial cancer. Accessed [December 15, 2025]. Available at: https://Www.Cancer.Org/Cancer/Types/Endometrial-Cancer/Detection-Diagnosis-Staging/Survival-Rates.Html

Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388:2159–70. https://doi.org/10.1056/NEJMoa2302312.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, Lee J-Y, Banerjee S, Maluf FC, Lorusso D, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024;391:44–55. https://doi.org/10.1056/NEJMoa2313811.

Article  CAS  PubMed  Google Scholar 

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody Drug Conjugate: The Biological Missile for Targeted Cancer Therapy. Signal Transduct Target Ther. 2022;7:93. https://doi.org/10.1038/s41392-022-00947-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee J-Y, Moroney JW, Colombo N, Roszak A, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389:2162–74. https://doi.org/10.1056/NEJMoa2309169.

Article  CAS  PubMed  Google Scholar 

Shvartsur A, Bonavida B. Trop2 and Its Overexpression in Cancers: Regulation and Clinical/Therapeutic Implications. Genes Cancer. 2015;6:84–105. https://doi.org/10.18632/genesandcancer.40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

The Human Protein Atlas. (n.d.). TACSTD2 RNA expression summary - the human protein atlas. Accessed December 20, 2025, from Https:// https://Www.Proteinatlas.Org/ENSG00000184292-TACSTD2/Summary/Rna

Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, Long H, Xu M, Ji Y, Xie J, et al. Preclinical Profiles of SKB264, a Novel Anti-TROP2 Antibody Conjugated to Topoisomerase Inhibitor, Demonstrated Promising Antitumor Efficacy Compared to IMMU-132. Front Oncol. 2022;12:951589. https://doi.org/10.3389/fonc.2022.951589.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Killock D. Sacituzumab Tirumotecan Improves OS in mTNBC. Nat Rev Clin Oncol. 2025;22:382–382. https://doi.org/10.1038/s41571-025-01022-0.

Article  PubMed  Google Scholar 

Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, Xie Y, Zhang Y, Cui J, Zhang Y, et al. Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC. N Engl J Med. 2025;NEJMoa2512071. https://doi.org/10.1056/NEJMoa2512071.

Wojtyla C, Ciebiera M, Kowalczyk D, Panek G. Cervical Cancer Mortality in East-Central European Countries. Int J Environ Res Public Health. 2020;17:4639. https://doi.org/10.3390/ijerph17134639.

Article  PubMed  PubMed Central  Google Scholar 

Chiba Y, Kojima Y, Yazaki S, Yoshida H, Takamizawa S, Kitadai R, Saito A, Okuma HS, Nishikawa T, Shimoi T, et al. Trop-2 Expression and the Tumor Immune Microenvironment in Cervical Cancer. Gynecol Oncol. 2024;187:51–7. https://doi.org/10.1016/j.ygyno.2024.04.022.

Article  CAS  PubMed  Google Scholar 

Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X. Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway. PLoS ONE. 2013;8:e75864. https://doi.org/10.1371/journal.pone.0075864.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horn L-C, Wolf B, Höhn AK, Hiller R, Brambs CE. Trop-2 Expression In Cervical Carcinoma (CX) - A Possible Target For The Antibody Drug Conjugate Sacituzumab. Int J Gynecol Cancer. 2025;35:100481. https://doi.org/10.1016/j.ijgc.2024.100481.

Article  Google Scholar 

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385:1856–67. https://doi.org/10.1056/NEJMoa2112435.

Article  CAS  PubMed  Google Scholar 

Vergote I, Van Nieuwenhuysen E, O’Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, Collins DC, Banerjee S, Mathews CA, Gennigens C, et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-Cx8 Study. J Clin Oncol. 2023;41:5536–49. https://doi.org/10.1200/JCO.23.00720.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Amico L, Menzel U, Prummer M, Müller P, Buchi M, Kashyap A, Haessler U, Yermanos A, Gébleux R, Briendl M, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7. https://doi.org/10.1186/s40425-018-0464-1.

Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, et al. Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Res. 2017;77:2686–98. https://doi.org/10.1158/0008-5472.CAN-16-2854.

Article  CAS  PubMed  Google Scholar 

Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mol Cancer Ther. 2018;17:1494–503. https://doi.org/10.1158/1535-7163.MCT-17-0749.

Article  CAS  PubMed  Google Scholar 

Huang L, Wang R, Xie K, Zhang J, Tao F, Pi C, Feng Y, Gu H, Fang J. A HER2 Target Antibody Drug Conjugate Combined with Anti-PD-(L)1 Treatment Eliminates hHER2 + Tumors in hPD-1 Transgenic Mouse Model and Contributes Immune Memory Formation. Breast Cancer Res Treat. 2022;191:51–61. https://doi.org/10.1007/s10549-021-06384-4.

Article  CAS  PubMed  Google Scholar 

Wu X, Wang J, An R et al. Efficacy and safety of Sacituzumab Tirumotecan (Sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Presented at: European Society for Medical Oncology (ESMO) Congress 2024; September 15, 2024; Lugano, Switzerland. Abstract 716MO.

Wang D, Yao W, Wang S, Zhang K, An R, Li B, Wang K, Li J, Wang F, Lee J-Y, et al. 1168P Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT) Monotherapy in Advanced/Metastatic Cervical Cancer: Results from a Phase I/II Study (MK-2870-001/KL264-01). Ann Oncol. 2025;36. https://doi.org/10.1016/j.annonc.2025.08.1804.

Salani R, Lindemann K, Lin Z, Nishio S, Oaknin A, Kurtz J-E, Valabrega G, Cáceres MV, Harter P, Gilbert L, et al. TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer. Int J Gynecol Cancer. 2025;35:100497. https://doi.org/10.1016/j.ijgc.2024.100497.

Article  Google Scholar 

Lheureux S, Braunstein M, Oza AM. Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine. CA Cancer J Clin. 2019;69:280–304. https://doi.org/10.3322/caac.21559.

Article  PubMed  Google Scholar 

Bax HJ, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, Grandits M, López-Abente J, Palhares LCGF, Chan Wah Hak C, et al. Folate Receptor Alpha in Ovarian Cancer Tissue and Patient Serum Is Associated with Disease Burden and Treatment Outcomes. Br J Cancer. 2023;128:342–53. https://doi.org/10.1038/s41416-022-02031-x.

Article  CAS  PubMed  Google Scholar 

Dum D, Taherpour N, Menz A, Höflmayer D, Völkel C, Hinsch A, Gorbokon N, Lennartz M, Hube-Magg C, Fraune C, et al. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiol J Immunopathol Mol Cell Biol. 2022;89:245–58. https://doi.org/10.1159/000522206.

Article  CAS  Google Scholar 

Wang D, Wang K, An R, Yu G, Zhang K, Wang D, Jiang K, Gao Y, Cheng Y, Liu Y, et al. 715MO Safety and efficacy of Sacituzumab Tirumotecan (Sac-TMT) in Patients (Pts) with previously treated advanced Endometrial Carcinoma (EC) and Ovarian Cancer (OC) from a phase II study. Ann Oncol. 2024;35. https://doi.org/10.1016/j.annonc.2024.08.777.

Lightfoot MDS, Rubinstein MM, Monk BJ, Eskander RN, Lutz K, Moore KN, Herzog TJ, Pothuri B. Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment. Int J Gynecol Cancer. 2025;35:101997. https://doi.org/10.1016/j.ijgc.2025.101997.

Article  PubMed  Google Scholar 

Giornelli GH, Mandó PA.